From Yahoo Finance: 2025-06-11 06:05:00

Investors in GLP-1 medications have not seen the expected gains despite the drugs’ popularity. ETFs tracking these drugs have underperformed, but companies remain optimistic. The main ETFs in the weight-loss drug segment are HRTS, OZEM, and THNR. Novo Nordisk, Eli Lilly, and Roche Holding AG are major holdings, leading to volatility in the healthcare field.

Investors are optimistic about the future of the weight-loss drug market despite challenges. New drugs like Zepbound and Olistat have entered the market, offering potential beyond weight loss. Recent trials suggest these drugs may protect against dementia. Short-term volatility is expected, but long-term prospects are promising.

Competition is increasing in the weight-loss drug marketplace, offering hope for investors. New drugs like Zepbound and Olistat have been approved by the FDA, with potential benefits beyond weight loss. Recent trials indicate these drugs may help prevent dementia. While short-term volatility is expected, long-term growth potential is promising.

Read more: Weight-Loss Drug ETFs Generate Skinnier Returns Than Expected